Results 101 to 110 of about 19,218 (261)

Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence

Dermatology and Therapy, 2018
Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy in humans, and as such it poses a significant healthcare burden. The majority of BCC cases are amenable to cure by surgical extirpation.
Evelyn Yu-Xin Tay, Yee-Leng Teoh, Matthew Sze-Wei Yeo   +2 more
doaj   +1 more source

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

, 2015
BACKGROUND The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of patients with advanced basal cell carcinoma for whom surgery is inappropriate.
Jouary, Thomas, K. Fife, Licitra, Lisa, Xynos, Ioannis, Dréno, Brigitte, D. S. Ernst, J. Hansson, B. Guillot, Fife, Kate, C. Dutriaux, Guillot, Bernard, R. Dummer, Basset-Seguin, Nicole, Ascierto, Paolo, R. Kunstfeld, Hauschild, Axel, Williams, Sarah, Hansson, Johan, Thomas, Luc, Meyer, Nicolas, J. . Grob, L. Licitra, Ernst, D Scott, Mortier, Laurent, Dutriaux, Caroline, Fittipaldo, Alberto, N. Meyer, N. Basset Seguin, Dummer, Reinhard, Kunstfeld, Rainer, L. Mortier, P. A. Ascierto, L. Thomas, Grob, Jean-Jacques, B. Dréno, T. Jouary, I. Xynos, S. Williams, Ascierto, Paolo A, A. Hauschild, A. Fittipaldo   +40 more
core   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

The prognostic and therapeutic significance of biological molecular markers in human anorectal carcinomas treated with 5'fluorouracil chemoradiation.

, 2005
Advances in tumour biology have led to studies of new biological markers, which may predict treatment response and clinical outcome independently of standard clinicopathological variables.
Mawdsley, S.K.V.
core  

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy

BMEMat, EarlyView.
This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang, Jiawei Cui, Jin Wang, Manfred F. Maitz, Rifang Luo, Yunbing Wang   +5 more
wiley   +1 more source

Locally advanced basal cell carcinoma in real life: Analysis of a cohort of 452 patients treated with systemic therapy from the CARADERM database

EJC Skin Cancer
Background: Locally advanced basal cell carcinoma (LaBCC) is a challenging condition. The European Association for Dermato-Oncology (EADO) suggested the classification of laBCC into 5 groups.
F. Herms, M. Djermane, M. Beylot-Barry, C. Chaffaut, S. Dalac, O. Dereure, J.J. Grob, L. Mortier, J. Lambert, N. Basset-Seguin   +9 more
doaj   +1 more source

Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases

Plastic and Reconstructive Surgery, Global Open, 2017
Summary:. Basal cell carcinoma (BCC) is the most common periocular skin cancer and can lead to significant morbidity. We assess the effectiveness of vismodegib, a first-in-class Hedgehog signaling pathway inhibitor, in the management of periocular and ...
Kai Yuen Wong, MA, MRCS, Kate Fife, MD, FRCP, FRCR, John T. Lear, MD, FRCP, Richard D. Price, MD, FRCS (Plast), Amer J. Durrani, MSc, FRCS (Plast)   +4 more
doaj   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source